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Pelvic inflammatory disease (PID) is a clinical syndrome of the female reproductive tract 
characterized by inflammation of the endometrium, fallopian tubes, or peritoneum (1). PID 
occurs when microorganisms ascend from the vagina or cervix to the fallopian tubes and 
other upper genital tract structures (1). PID can result from untreated bacterial infections, 
including chlamydia and gonorrhea, and can lead to infertility, ectopic pregnancy, and 
chronic pelvic pain (1). Because there is no single diagnostic test for PID, clinicians rely on 
nonspecific signs and symptoms for diagnosis. The purpose of these analyses was to assess 
the burden of self-reported PID in a nationally representative sample using data from the 
National Health and Nutrition Examination Survey (NHANES) 2013–2014 cycle. Starting in 
2013, NHANES female participants aged 18–44 years were asked about a lifetime history of 
PID diagnosis. Based on these data, the estimated prevalence of self-reported lifetime PID 
was 4.4% in sexually experienced women of reproductive age (18–44 years). The prevalence 
of self-reported lifetime PID was highest in women at increased risk, such as women 
reporting a previous sexually transmitted infection (STI) diagnosis. Stratified by race/
ethnicity and having a previous STI diagnosis, non-Hispanic black (black) and non-Hispanic 
white (white) women reporting a previous STI diagnosis had nearly equal self-reported 
lifetime PID prevalence (10.0% versus 10.3%). However, the lifetime prevalence of PID 
among black women was 2.2 times that among white women if no previous STI was 
diagnosed (6.0% versus 2.7%). These findings suggest that PID is prevalent and associated 
with previous STI diagnoses; therefore, it is important for clinicians to screen female 
patients for chlamydia and gonorrhea to reduce the incidence of PID.
NHANES is a cross-sectional, complex, multistage survey designed to be nationally 
representative of the noninstitutionalized U.S. civilian population (https://www.cdc.gov/
nchs/nhanes.htm). Participants undergo a medical examination and are interviewed in 
person, during which time questions regarding sexual and reproductive health are asked. In 
NHANES 2013–2014, a total of 1,444 women aged 18–44 years were interviewed and had a 
medical exam; the response rate was 71.1%. The 1,171 (81%) reproductive-aged female 
participants who responded “Yes” to the question, “Have you ever had vaginal, anal, or oral 
sex?” were defined as sexually experienced and were the focus of these analyses. 
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Participants who responded “Yes” to the question, “Have you ever been treated for an 
infection in your fallopian tubes, uterus or ovaries, also called a pelvic infection, pelvic 
inflammatory disease, or PID?” met the case definition of a lifetime PID diagnosis. Having 
received a diagnosis of a previous STI was defined as having had a chlamydia or gonorrhea 
infection during the past 12 months or ever having had herpes, human papillomavirus, or 
genital warts. The prevalence of self-reported lifetime PID, prevalence ratios (PRs), and 95% 
confidence intervals (CIs) were estimated overall and by various characteristics. 
Associations were measured by use of the Rao-Scott chi-square test. All analyses were 
conducted using SAS statistical software (version 9.3) and accounted for the complex survey 
design and sampling weights. As such, these results are nationally representative. The 
mobile examination center exam sampling weights were used to weight the data. Population 
counts were estimated by multiplying weighted prevalence estimates by the average of the 
American Community Survey estimates during 2013–2014.
Among 1,171 sexually experienced reproductive-aged women in NHANES 2013–2014, the 
prevalence of self-reported lifetime PID was 4.4% (Table), indicating that approximately 2.5 
million women aged 18–44 nationwide have received a diagnosis of PID in their lifetime 
(95% CI = 1.8–3.2 million). No significant differences existed in prevalence of a lifetime 
PID diagnosis by age, race/ethnicity, or socioeconomic factors, such as income-poverty 
ratio, current health insurance coverage, or having a current usual place for health care.
Significant differences in the prevalence of lifetime PID were observed by the sexual 
behaviors and sexual health histories of respondents. The prevalence of self-reported lifetime 
PID among women whose age of sexual debut was <12 years was approximately eight times 
that of women whose age of sexual debut was =18 years (PR = 8.6). Similarly, the lifetime 
PID prevalence among women with =10 lifetime male vaginal sex partners was 
approximately three times that of women with a single partner (PR = 3.6). The prevalence of 
lifetime PID was approximately double in women reporting lesbian/bisexual versus 
heterosexual orientation (PR = 2.1), and the prevalence among women reporting a previous 
STI diagnosis was approximately three times that of women without a previous STI 
diagnosis (PR = 3.3).
In stratified analyses (Figure), the prevalence of self-reported lifetime PID among women 
reporting a previous STI diagnosis was similar in whites and blacks (10.0% [95% CI = 4.4–
15.6] versus 10.3% [95% CI = 1.3–19.4], p = 0.97). However, among women with no 
previous STI diagnosis, the prevalence of self-reported lifetime PID in black women was 2.2 
times the prevalence in white women (black: 6.0% [95% CI: 3.4–8.6] versus white: 2.7% 
[95% CI: 1.1–4.4], p = 0.01).
Discussion
Based on NHANES 2013–2014 data, an estimated 2.5 million women aged 18–44 years in 
the United States reported a lifetime history of PID diagnosis. The increased prevalence 
among women reporting a previous STI diagnosis and other behaviors that increase risk for 
acquiring an STI underscores the need for STI prevention and control activities. The higher 
prevalence among black versus white women without a previous STI diagnosis suggests that 
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black women might be more likely to have had an undiagnosed, asymptomatic STI or less 
likely to have received or reported a diagnosis for a symptomatic infection, possibly because 
of decreased access to care (2).
PID is not nationally notifiable but is reportable in some states. Few studies have assessed 
the incidence of PID using nationally representative data. Estimates from the National 
Survey of Family Growth found a similar prevalence of self-reported lifetime PID treatment 
among reproductive-aged women (5.7% during 2006–2010) and variations in self-reported 
lifetime PID treatment by sexual behaviors (3); women with a younger age of sexual debut 
and a higher number of lifetime vaginal sex partners were more likely to have received 
treatment for PID. The results of that study indicated that black race, having less than a high 
school education, and an income <150% of the federal poverty level were associated with 
receipt of PID treatment.
The findings in this study are subject to at least four limitations. First, small sample sizes led 
to unstable estimates and wide CIs. Hence, these results should be interpreted cautiously. 
Second, NHANES PID data are based on self-report, an inherent problem of which is social-
desirability bias. Third, given that PID is often asymptomatic and difficult to diagnose 
because of the lack of a diagnostic test and the low sensitivity and specificity associated with 
the use of a clinical case definition, estimates in this report might underestimate the actual 
prevalence of PID. Finally, temporality could not be established for all factors, and as such, 
there is no way to know whether the occurrence of certain factors (i.e., health insurance, 
access to health care, previous STI diagnoses) occurred before the PID diagnosis.
PID can result from untreated bacterial infections, including chlamydia and gonorrhea, both 
of which are treatable and preventable. Each case of PID results in an estimated average cost 
of $3,202 (4). Chlamydia and gonorrhea are the most commonly reported STIs in the United 
States, with approximately 1.5 million chlamydia and approximately 400,000 gonorrhea 
infections reported in 2015 (5). Most chlamydia and gonorrhea infections are asymptomatic 
in women and many go undiagnosed and untreated (6). Results from randomized controlled 
trials suggest that chlamydia screening is associated with a decreased incidence of PID (7,8). 
The U.S. Preventive Services Task Force recommends that all sexually active women aged 
<25 years and older women at increased risk for infection be screened for chlamydia and 
gonorrhea (9).
Using nationally representative data, this study found a substantial prevalence of PID in the 
United States. Lifetime prevalence of PID was highest in women with sexual behaviors and 
a sexual health history putting them at increased risk for STIs, including having had a prior 
STI diagnosis, and differed by race/ethnicity in those without a prior STI diagnosis. Given 
the potential for asymptomatic infections to lead to PID and the costs associated with 
treatment, it is important for clinicians to adhere to U.S. Preventive Services Task Force 
guidelines for chlamydia and gonorrhea screening in an effort to decrease the PID burden in 
sexually experienced women of reproductive age nationwide (9).
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What is already known about this topic?
Pelvic inflammatory disease (PID) has various etiologies, including untreated chlamydia 
and gonorrhea infections, and is a potential sequela of these infections, with serious and 
costly outcomes. Chlamydia and gonorrhea infections are largely asymptomatic among 
women, and as such, most infections are undiagnosed and untreated.
What is added by this report?
In the National Health and Nutrition Examination Survey 2013–2014 cycle, the 
prevalence of a self-reported lifetime PID diagnosis was 4.4% among sexually 
experienced reproductive-aged women, equating to 2.5 million prevalent PID cases in 
women aged 18–44 years nationwide. Prevalence of a self-reported lifetime PID 
diagnosis varied by sexual behaviors and sexual health history and differed by race/
ethnicity in women without a prior STI diagnosis.
What are the implications for public health practice?
These findings highlight differences in reproductive health by sexual behaviors and 
sexual health history. Given the potential of asymptomatic infection to lead to PID and 
the substantial costs associated with treatment, it is important that clinicians follow 
chlamydia and gonorrhea screening recommendations for women to decrease the 
incidence of PID.
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FIGURE. Prevalence of self-reported lifetime pelvic inflammatory disease* among sexually 
experienced women† aged 18–44 years (n = 1,171), by race/ethnicity and previous STI 
diagnosis§,¶ — National Health and Nutrition Examination Survey, United States, 2013–2014
Abbreviation: STI = sexually transmitted infection.
* Prevalence estimates based on response to the question, “Have you ever been treated for an 
infection in your fallopian tubes, uterus or ovaries, also called a pelvic infection, pelvic 
inflammatory disease, or PID?” Estimates were weighted to be nationally representative of 
the U.S. population, accounting for unequal probabilities of selection and nonresponse.
†Based on a response of “Yes” to the question, “Have you ever had vaginal, anal, or oral 
sex?”
§Participants who were told by a doctor or other health care professional in the last 12 
months that they had chlamydia or gonorrhea or were ever told they have herpes, human 
papilloma virus, or genital warts.
¶Bars indicate 95% confidence interval. Prevalence estimates among non-Hispanic black 
women with a previous STI diagnosis have a relative standard error >40% but <50%.
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TABLE
Prevalence of self-reported lifetime pelvic inflammatory disease* among sexually experienced women† aged 
18–44 years (n = 1,171), by selected characteristics — National Health and Nutrition Examination Survey, 
United States, 2013–2014.
Characteristic Sample size no. Prevalence (%)§ (95% CI) Prevalence ratio¶ (95% CI)
Total 1,171 4.4 (3.1–5.7) — (—)
Age group (yrs) (p = 0.28)**
18–24 327 2.9†† (0.8–5.0) Ref (—)
25–29 185 4.6†† (1.4–7.9) 1.6 (0.6–4.1)
30–34 212 5.0†† (1.8–8.2) 1.7 (0.7–4.3)
35–39 209 3.5 (1.5–5.4) 1.2 (0.5–2.7)
40–44 238 6.7 (2.6–10.8) 2.3 (0.8–6.6)
Race/Ethnicity (p = NC)**
White, non-Hispanic 436 4.4 (2.8–6.0) Ref (—)
Black, non-Hispanic 245 6.8 (4.0–9.5) 1.5 (0.9–2.5)
Asian, non-Hispanic 130 0.0 (—) — (—)
Mexican American 195 —§§ (—§§) —§§ (—§§)
Education level (p = 0.21)**
Less than high school 212 4.3†† (1.0–7.6) Ref (—)
High school graduate/GED 243 3.1†† (1.1–5.2) 0.7 (0.3–1.8)
Some college/Associates degree 430 6.2 (3.2–9.2) 1.5 (0.6–3.7)
College graduate or above 286 3.0¶¶ (0.4–5.7) 0.7 (0.2–2.9)
Marital status (p = 0.56)**
Married/Living with partner 618 5.0 (2.5–7.6) Ref (—)
Divorced/Separated/Widowed 120 5.3¶¶ (0.6–9.9) 1.0 (0.4–3.0)
Never married 309 3.5 (1.3–5.8) 0.7 (0.3–1.9)
Income-poverty ratio*** (p = 0.50)**
<150% FPL 500 5.1 (2.9–7.3) Ref (—)
150%–299% FPL 244 4.7†† (1.0–8.4) 0.9 (0.3–2.5)
=300% FPL 357 3.2†† (0.9–5.4) 0.6 (0.3–1.5)
Health insurance coverage (p = 0.20)**
Covered 860 4.0 (2.5–5.5) Ref (—)
Not covered 303 6.1 (2.6–9.6) 1.5 (0.7–3.2)
Has a usual place for health care (p = 0.87)**
Yes 952 4.4 (2.6–6.1) Ref (—)
No 219 4.7†† (1.2–8.3) 1.1 (0.4–2.9)
Type of place for usual health care (p = NC)**
Doctor’s office/HMO 655 3.8 (1.8–5.9) Ref (—)
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Characteristic Sample size no. Prevalence (%)§ (95% CI) Prevalence ratio¶ (95% CI)
Clinic/health center 219 6.0†† (1.2–10.9) 1.6 (0.6–4.2)
Hospital outpatient 63 —§§ (—§§) —§§ (—§§)
department/ED
Age at sexual debut, in years (p = 0.0002)**
=18 475 2.7 (1.2–4.2) Ref (—)
16–17 371 4.6 (1.7–7.5) 1.7 (0.7–4.3)
14–15 228 4.9 (2.5–7.4) 1.8 (0.9–3.6)
12–13 79 8.9 (3.3–14.5) 3.4 (1.4–8.5)
<12 18 23.6¶¶ (0.9–46.2) 8.6 (2.7–27.9)
Sexual orientation (p = NC)**
Heterosexual 1,042 4.1 (2.8–5.4) Ref (—)
Lesbian/Bisexual 102 8.7†† (2.3–15.1) 2.1 (0.9–4.8)
No. male lifetime vaginal sex partners (p = 0.0005)**
1 292 2.5¶¶ (0.1–4.8) Ref (—)
2–3 230 2.0†† (0.3–3.7) 0.8 (0.3–2.4)
4–9 400 4.1 (2.1–6.0) 1.7 (0.7–4.2)
=10 249 8.7 (5.0–12.4) 3.6 (1.2–10.7)
Previous STI diagnosis††† (p<0.0001)**
No 978 3.1 (1.9–4.2) Ref (—)
Yes 193 10.2 (6.0–14.3) 3.3 (1.9–5.7)
Abbreviations: CI = confidence interval; ED = emergency department; FPL = Federal Poverty Level; GED = General Educational Development 
certification; HMO = health maintenance organization; NC = not calculated; STI = sexually transmitted infection.
*
Prevalence estimates based on response to the question “Have you ever been treated for an infection in your fallopian tubes, uterus or ovaries, also 
called a pelvic infection, pelvic inflammatory disease, or PID?”
†
Based on a response of “Yes” to the question “Have you ever had vaginal, anal, or oral sex?”
§
Estimates were weighted to be nationally representative of the U.S. population, accounting for unequal probabilities of selection and nonresponse.
¶
Respondents with missing or unknown values were excluded from prevalence ratio calculations.
**
Calculated via use of the Rao-Scott chi-square test. The overall p-values could not be calculated (p = NC) for some characteristics with zero 
prevalence in categories not shown (e.g., “other” category for sexual orientation).
††
Relative standard error >30% but <40%.
§§
Relative standard error >50%; estimates are suppressed.
¶¶
Relative standard error >40% but <50%.
***
Ratio of family income to poverty level as defined by the U.S. Census Bureau.
†††
Participants who were told by a doctor or other health care professional in the last 12 months that they had chlamydia or gonorrhea or were ever 
told they have herpes, human papilloma virus, or genital warts.
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